While SO4(2-) concentrations in runoff are decreasing in many catchments in Europe, present day S output still exceeds the S input for most forested catchments in Europe and North America. Here we report that a large part of the observed SO4(2-) in the runoff at a large-scale catchment study site (the Gårdsjön roof experiment in southwestern Sweden) originates from the organic S pool in the O horizon. Budget estimates comparing soil S pools showed reductions in the S pool of 57 mmol of S m(-2) in the O horizon and 26 mmol of SO4(2-) m(-2) in the mineral Bs horizon after excluding anthropogenic deposition for four years. There was an increase of about 1% per hundred in the delta34S(SO4), value of the mineral soil SO4(2-) between 1990 and 1995 (average and 95% confidence interval of 6.2 +/- 0.6 and 7.7 +/- 0.6% per hundred, respectively), but the delta34S(SO4) values in the E horizon are still much lower than the sprinkler water input of +19.7% per hundred, although the horizon has only a small extractable SO4(2-) pool. After nine years (1991-2000) of artificially supplying S inputs comparable with those amounts supplied by preindustrial rain, the amount of S in runoff still exceeded the input by 30%. This extra 30% corresponds to a loss of 3 mmol of S m(-2) year(-1), compared to the soil S organic O horizon pool of 1098 mmol m(-2) in 1990, suggesting that recovery is delayed for decades, at least.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/es048169q | DOI Listing |
Neuropathol Appl Neurobiol
February 2025
Department of Neurology, Shandong Key Laboratory of Mitochondrial Medicine and Rare Diseases, Research Institute of Neuromuscular and Neurodegenerative Diseases, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Background: Progressive external ophthalmoplegia (PEO) is a classic manifestation of mitochondrial disease. However, the link between its genetic characteristics and clinical presentations remains poorly investigated.
Methods: We analysed the clinical, pathological and genetic characteristics of a large cohort of patients with PEO, based on the type of their mtDNA variations.
Diabetologia
January 2025
Internal Medicine Department, Endocrine Division (SEMPR), Universidade Federal do Paraná, Curitiba, Brazil.
Aims/hypothesis: COMBINE 2 assessed the efficacy and safety of once-weekly IcoSema (a combination therapy of basal insulin icodec and semaglutide) vs once-weekly semaglutide (a glucagon-like peptide-1 analogue) 1.0 mg in individuals with type 2 diabetes inadequately managed with GLP-1 receptor agonist (GLP-1 RA) therapy, with or without additional oral glucose-lowering medications.
Methods: This 52 week, randomised, multicentre, open-label, parallel group, Phase IIIa trial was conducted across 121 sites in 13 countries/regions.
BMJ Open
January 2025
Werlabs AB, Stockholm, Sweden
Purpose: There is limited research on individuals undergoing self-initiated health examinations, and the Werlabs cohort will be a base for such research.
Participants: All individuals aged 18 or older who had undertaken a self-initiated health examination at Werlabs AB with at least one recorded value of creatinine or cholesterol in Sweden (from 1 January 2015 through 31 December 2023) was included. Medical history and anthropometric measurements were self-reported through an online questionnaire.
World J Diabetes
January 2025
Department of Endocrinology, Beijing Haidian Hospital, Beijing 100080, China.
Background: Treating diabetes in dialysis patients remains a challenge, with many hypoglycemic drugs requiring dose adjustments or avoidance in these patients.
Case Summary: This report describes an 83-year-old female patient with a 30-year history of type 2 diabetes (T2DM) who had struggled to control her blood sugar for more than a year. She had a history of high blood pressure for 30 years, had undergone continuous ambulatory peritoneal dialysis for more than two years, was 163 cm tall, weighed 77 kg, and had a body mass index of 28.
BMJ Open
December 2024
Division of Research, Kaiser Permanente, Pleasanton, California, USA.
Objectives: The US Preventive Services Task Force recommends screening of adults aged 35-70 with a body mass index ≥25 kg/m for type 2 diabetes and referral of individuals who screen positive for pre-diabetes to evidence-based prevention strategies. The diabetes burden in the USA is predicted to triple by 2060 necessitating strategic diabetes prevention efforts, particularly in areas of highest need. This study aimed to identify pre-diabetes hotspots using geospatial mapping to inform targeted diabetes prevention strategies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!